Collecting biological samples to study blood disorders
Official title: Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
Run by National Institutes of Health Clinical Center (CC) · NCT03937817 · Data updated 2026-11-12
This study is collecting samples from people with blood disorders and healthy volunteers to see how certain genetic factors affect these conditions and overall health.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | National Institutes of Health Clinical Center (CC) NIH |
| Locations | 1 site (Bethesda, Maryland) |
| Status | Recruiting |
| Started | September 25, 2019 |
| Main results expected | March 31, 2029 |
| Study ends | March 31, 2029 |
| Registry record updated | October 2, 2026 |
| Trial ID | NCT03937817 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals aged 18-70 with blood disorders or healthy volunteers without blood disorders.
✕Probably not a fit
Patients who are pregnant or have active infections such as hepatitis B, hepatitis C, or HIV may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to collect human biospecimens from individuals with blood disorders such as alpha and beta thalassemia and sickle cell disease, as well as healthy volunteers. Participants aged 18-70 will undergo screening and provide various biological samples, including saliva, urine, blood, and fat samples, over a period of five years. The collected specimens will be used to develop laboratory assays and further research into the roles of globin variants in relation to these blood disorders and their impact on human physiology.
Why it matters
Potential benefit: If successful, this research could lead to a better understanding of blood disorders and improved diagnostic and therapeutic strategies.
How similar studies have gone: Other studies have successfully utilized similar approaches to collect biospecimens for research into blood disorders, indicating a promising avenue for this type of investigation.
Who can join: the full rules
Show full inclusion / exclusion criteria
* PARTICIPANT INCLUSION CRITERIA:
1. Aged 18-70 years.
2. Able to provide informed consent.
3. Willing to allow biological samples to be stored for future research.
4. Willing to provide one or more of the following tissues: saliva, urine, blood, blood waste products, adipose tissue, bronchial brushing, and/or BAL samples.
5. Willing to allow genetic testing on collected biological samples.
PARTICIPANT EXCLUSION CRITERIA:
* Exclusion Criteria for All Participants
The following exclusion criteria apply to all participants who will provide any of the following samples in-person at the NIH CC: saliva, urine, blood, blood waste products, adipose tissue, bronchial brushing, and/or BAL samples:
1. Pregnancy.
2. Positive testing for hepatitis B virus, hepatitis C virus, or HIV (as determined by serum screening tests or relevant viral quantitative studies.)
3. Any condition that requires active medical intervention or monitoring to avert serious danger to the individual s health or wellbeing.
4. Any condition that, in the opinion of the PI, contraindicates participation in this study.
* Additional Exclusion Criteria for Individuals Giving Blood for Research
1\. Hemoglobin \< 10 g/dL for healthy female volunteers, \< 12 g/dL for healthy male volunteers, or \< 6 g/dL for participants with sickle cell disease or other chronic anemias.
-Additional Exclusion Criteria for Adipose Tissue Biopsy
Individuals meeting any of the following criteria will be excluded from undergoing adipose tissue biopsy. If the participant no longer meets any of these criteria at a later time, then they will be allowed to undergo this procedure.
1. Currently taking anticoagulation medication.
2. Platelets \< 100,000/microL.
3. History of keloid formation (or irregular fibrous tissue formed at the site of a scar or injury).
4. History of adverse reactions to lidocaine or other local anesthetics.
5. Any condition that, in the opinion of the PI, contraindicates this procedure.
Use of aspirin (or acetylsalicylic acid) and nonsteroidal anti-inflammatory drugs (NSAIDs) are permitted.
-Additional Exclusion Criteria for Bronchoscopy
Individuals meeting any of the following criteria will be excluded from undergoing bronchoscopy. If the participant no longer meets any of these criteria at a later time, then they will be allowed to undergo this procedure.
1. Prothrombin time (PT) \> 1 second above the upper limit of normal (ULN) or international normalized ratio \> 1.3.
2. Partial thromboplastin time (PTT) \> 1 second above ULN.
3. Platelets \< 150,000/microL.
4. Currently taking anticoagulation medication.
5. Use of aspirin within 2 weeks of the bronchoscopy or NSAIDs within 2 days of the bronchoscopy.
6. Diagnosis of a pulmonary disorder (eg, asthma, chronic bronchitis, cystic fibrosis, or bronchiectasis).
7. Respiratory tract infection within the last 4 weeks.
8. History of adverse reactions to systemic and/or local anesthetics that will be used for this procedure.
9. History of cigarette smoking within the past 3 months.
10. History of chronic opioid use.
11. History of drug or alcohol abuse.
12. Post-bronchodilator forced expiratory volume in 1 second (FEV1) \< 40% of predicted or pre-bronchodilator FEV1 \< 35% of predicted.
13. Active bronchospasm on physical examination.
14. History of lidocaine allergy.
15. Any condition that, in the opinion of the PI, contraindicates this procedure.
Co-enrollment guidelines: Participants may be co-enrolled in other studies. However, the PI must be notified of co-enrollment.
Where it's running
-
National Institutes of Health Clinical Center
Bethesda, Maryland, United States Recruiting
Study contacts
- Principal investigator: Hans C Ackerman, M.D. — National Institute of Allergy and Infectious Diseases (NIAID)
- Study coordinator: Mary J Jackson, R.N.
- Email: alpha.study@nih.gov
- Phone: (301) 761-5667
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Cerebrovascular Reactivity Testing with HD-DOT in Sickle Cell Patients
This study tests whether high-density diffuse optical tomography can measure brain blood flow and oxygen use in people with sickle cell disease, to see how these signals relate to stroke risk.
-
Lotilaner safety and blood activity in healthy adults in Mali
This Phase 1b study tests if a single dose of lotilaner is safe, tolerable, and shows mosquito-killing activity in healthy adults living in Mali.
-
Adapting and testing PEN-Plus in Zambian primary care
Aiming to see if the PEN-Plus package can be adapted and used in two Zambian hospitals to better manage chronic diseases like heart disease, diabetes, hypertension, and sickle cell in primary care.
-
See if the R21/Matrix-M malaria vaccine works in real-world settings for kids under 5
This study tests how well the R21/Matrix-M vaccine protects children under 5 in Burkina Faso and Uganda when used in typical clinical care.
-
Newborn Sickle Cell Screening in Mozambique
We’re testing a three-part plan to help babies in Mozambique get diagnosed early for sickle cell disease and start care quickly.
-
Optimizing Hydroxyurea in Children with Sickle Cell in Africa
This study tests whether raising hydroxyurea to a maximum tolerated dose is safe and beneficial for Ugandan children with sickle cell anemia already taking a fixed daily dose.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.